XQ-001 / Chengdu Brilliant Pharma - LARVOL DELTA

Late Breaking Abstract - Safety, tolerability, and pharmacokinetics of inhaled TGF-β1 modulator in healthy Chinese subjects: a randomized, double-blind, placebo-controlled phase 1 trial (ERS 2025) - "No evidence of accumulation of XQ-001was found on day 7, with a Rac Cmax of 1.01-1.07 and Rac AUC of 1.16-1.19. The favorable pharmacokinetic and safety results support further clinical development of XQ-001 in IPF patients."

Clinical • Late-breaking abstract • P1 data • PK/PD data • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases • TGFB1